StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Free Report) in a report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
NASDAQ BLPH opened at $0.04 on Thursday. The company has a market cap of $428,155.00, a PE ratio of -0.04 and a beta of 0.73. The firm’s 50 day moving average price is $0.04 and its 200-day moving average price is $0.05. Bellerophon Therapeutics has a 52-week low of $0.03 and a 52-week high of $0.46.
Bellerophon Therapeutics Company Profile
See Also
- Five stocks we like better than Bellerophon Therapeutics
- Top Biotech Stocks: Exploring Innovation Opportunities
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- 3 Healthcare Dividend Stocks to Buy
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- The 3 Best Retail Stocks to Shop for in August
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.